Healthcare Technology Report June 12, 2024
Inflammatory disease research has surged as a focal point in drug development, with 2024 witnessing eight major buyouts of immune drug developers, surpassing oncology mergers and acquisitions. Notable deals include Merck’s $10.8 billion acquisition of Prometheus Biosciences and Roche’s $7.1 billion acquisition of Telavant. This heightened interest has extended to startups, with companies like Acelyrin, Apogee Therapeutics, and Kyverna Therapeutics launching significant initial public offerings. Lycia Therapeutics, Capstan Therapeutics, and Mirador Therapeutics have all raised more than $100 million in investment rounds in just the first half of 2024.
Significantly benefiting from this investment surge is AltruBio. Following a rebranding and the appointment of...
Today's Sponsors
Today's Sponsor